Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
427 results
  • Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist. [Review]
    J Adv Pract Oncol 2019 Jan-Feb; 10(1):62-67Uritsky TJ
  • Opioid-induced constipation (OIC) is a common adverse effect associated with opioid therapy, with many patients never developing tolerance to this effect. There are many traditional laxatives available to help patients combat this symptom, yet OIC may not reliably respond to conventional treatment. Peripherally acting µ-opioid receptor antagonists (PAMORAs) have a place in the treatment of refrac…
  • [Management of adverse effects of opioid therapy]. [Journal Article]
    Laryngorhinootologie 2019; 98(7):473-479Wirz S
  • More than 6 million people in Germany suffer from chronic pain which greatly impairs their wellbeing. Often the only therapeutic option is to use class 2 or 3 analgesic opioids in the WHO classification, as class 1 analgesics may be toxic or of limited efficacy. However, the high incidence of opioid side effects leads to high discontinuation rates. Thus, the success of opioid treatment is also hi…
  • Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis. [Journal Article]
    Sci Rep 2019; 9(1):9625Nelson KK, Schattner MA, Mendelsohn RB
  • Opioid-induced constipation (OIC) has become increasingly prevalent with the rise of prescription opioid use and can significantly impact quality of life, especially in patients with advanced illness. Methylnaltrexone has proven effective in treating cancer patients with OIC who have not responded adequately to conventional laxative therapy, though use is relatively contraindicated in those with …
New Search Next